A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.

Inclusion Criteria: * Subjects who fully understood this trial and voluntarily signed the informed consent form; * Men or women ≥ 18 years old; * ECOG Performance Status (PS) 0 or 1; * Life expectancy \> 3 months. Exclusion Criteria: * Received any treatment with inhibitors against KRAS G12C mutation at any time, e.g., AMG 510, MRTX 849, etc.; * Patients requiring medications that can potentially prolong QTc interval; * Other conditions that the investigator considers to be unsuitable for participation in this study.